CONNECT WITH US
HealthTech

HealthTech

Aspen, Bambusa target $135M IPOs; AstraZeneca vs. Takeda in gastric cancer ADCs

Endpoints News logo

Published on

Add as a preferred source on Google
Aspen, Bambusa target $135M IPOs; AstraZeneca vs. Takeda in gastric cancer ADCs

As­pen and Bam­busa tar­get $135M IPOs; As­traZeneca vs. Take­da in gas­tric can­cer AD­Cs

Plus news about Hutchmed, John­son & John­son, Jazz Phar­ma­ceu­ti­cals, No­var­tis, Roche and Oru­ka Ther­a­peu­tics.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

A he­pati­tis B hold lift­ed and drug tabled; Ul­tomiris' ac­cel­er­at­ed ap­proval October 22, 2026

Al­con and Ope­nAI make ac­qui­si­tions; Tezspire's lat­est Phase 3 win October 21, 2026

BioN­Tech, Du­al­i­ty­Bio pon­der next steps for HER2 ADC af­ter 'mod­est' breast can­cer re­sults

Mer­ck and Mod­er­na's can­cer vac­cine da­ta were 'a tri­umph of sci­ence.' And now, the work be­gins

Roche takes vic­to­ry lap with lung can­cer pil­l's win over Am­gen, Bris­tol My­ers

Swiss biotech Wind­ward Bio files for Nas­daq IPO to fund Chi­na-de­rived as­sets and in-house R&D



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.